Skip to content

US · ALLR · BIOTECHNOLOGY

Allarity Therapeutics, Inc. (ALLR) intrinsic value and stock valuation

$0.79as of 2026-11-21 · Mkt cap 21.16M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Allarity Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ALLR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ALLR’s statements →

Allarity Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Tarpon Springs, FL 34689 allarity.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$320K
20132025
Net income
-$-11.23M
20132025
Free cash flow
-$-14.83M
20132025
Total equity
$9.83M-16.7% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$320K$0.00$0.00$0.00$0.00
Operating income-$-12.61M-$-27.24M-$-17.13M-$-34.46M-$-26.56M
Net income-$-11.23M-$-24.52M-$-11.9M-$-16.06M-$-26.65M
EPSd-$-780.95K-$-15.23M-$-3.58M-$-1.61B-$-2.67B
Operating cash flow-$-14.82M-$-17.35M-$-12.74M-$-16.82M-$-15.05M
Capital expenditure-$-10K-$-300K$0.00-$-20K$0.00
Free cash flow-$-14.83M-$-17.65M-$-12.74M-$-16.84M-$-15.05M
Total assets$18.3M$22.7M$11.9M$14.5M$49.6M
Total debt$1.4M$1.35M$1.3M$3.73M$1.09M
Net debt-$-13.29M-$-18.18M$1.13M$1.71M-$-18.47M
Total equity$9.83M$11.8M-$-2.75M$1.89M$18.8M
Cash and short-term investments$14.7M$19.5M$170K$2.03M$19.9M
Income statement
20252024202320222021
Revenue$320K$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$120K$110K
Gross profit$320K$0.00$0.00-$-120K-$-110K
Research and development expenses$6.6M$6.1M$7.1M$6.93M$14.2M
Selling, general and administrative expenses$6.32M$11.4M$10M$9.96M$12.4M
Other expenses$0.00$9.7M$0.00$17.6M$0.00
Operating expenses$12.9M$27.2M$17.1M$34.5M$26.6M
Cost and expenses$12.9M$27.2M$17.1M$34.5M$26.6M
Interest income$800K$530K$20K$30K$0.00
Interest expense$180K$650K$500K$220K$640K
Depreciation and amortization-$-10K$10K$40K$60K$110K
Ebitda-$-11.05M-$-24.23M-$-11.28M-$-17.3M-$-25.77M
Operating income-$-12.61M-$-27.24M-$-17.13M-$-34.46M-$-26.56M
Total other income/expenses, net$1.37M$2.35M$5.31M$16.9M$40K
Income before tax-$-11.23M-$-24.9M-$-11.82M-$-17.58M-$-26.52M
Income tax expense$0.00-$-380K$80K-$-1.52M$130K
Net income-$-11.23M-$-24.52M-$-11.9M-$-16.06M-$-26.65M
Weighted average shares outstanding$14.4M$1.61M$3.32M$10K$10K
Weighted average diluted shares outstanding$14.4M$1.61M$3.32M$10K$10K
Balance sheet
20252024202320222021
Cash and short-term investments$14.7M$19.5M$170K$2.03M$19.9M
Net receivables$900K$2.23M$950K$870K$1.34M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$17.9M$22.3M$1.97M$4.97M$21.4M
Property, plant and equipment, net$330K$310K$20K$30K$90K
Goodwill and intangible assets$0.00$0.00$9.87M$9.55M$28.1M
Long-term investments$0.00$0.00$0.00$0.00$350K
Total non-current assets$330K$310K$9.89M$9.58M$28.2M
Total assets$18.3M$22.7M$11.9M$14.5M$49.6M
Accounts payable$4.28M$4.18M$8.42M$6.25M$700K
Short-term debt$1.4M$1.35M$1.3M$2.65M$100K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.43M$10.8M$14.2M$11.2M$20.7M
Long-term debt$0.00$0.00$0.00$1.08M$990K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$450K$1.43M$10.1M
Capital lease obligations$0.00$0.00$0.00$10K$110K
Total liabilities$8.43M$10.8M$14.6M$12.7M$30.9M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-130.2M-$-118.97M-$-94.45M-$-82.55M-$-66.49M
Accumulated other comprehensive income (loss)-$-1.02M-$-350K-$-410K-$-720K-$-600K
Total equity$9.83M$11.8M-$-2.75M$1.89M$18.8M
Total investments$0.00$0.00$0.00$0.00$700K
Total debt$1.4M$1.35M$1.3M$3.73M$1.09M
Net debt-$-13.29M-$-18.18M$1.13M$1.71M-$-18.47M
Cash flow statement
20252024202320222021
Net income-$-11.23M-$-24.52M-$-11.9M-$-16.06M-$-26.65M
Depreciation and amortization-$-10K$10K$40K$60K$110K
Stock-based compensation$480K$70K-$-70K$1.75M$6.37M
Change in working capital-$-5.68M$60K$3.35M-$-330K$5.57M
Accounts receivable-$-100K$40K-$-30K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.14M-$-4.11M$2.17M$6.21M-$-1.31M
Net cash provided by operating activities-$-14.82M-$-17.35M-$-12.74M-$-16.82M-$-15.05M
Investments in property, plant and equipment-$-10K-$-300K$0.00-$-20K$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K-$-300K$0.00$790K$1M
Common stock issued$13.8M$40.3M$16.9M$0.00$32.1M
Common stock repurchased-$-3.19M-$-3.5M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.7M$36.8M$11M-$-1.31M$33.8M
Net change in cash-$-4.85M$19.4M-$-1.86M-$-17.53M$19.3M
Cash at end of period$14.7M$19.5M$170K$2.03M$19.6M
Operating cash flow-$-14.82M-$-17.35M-$-12.74M-$-16.82M-$-15.05M
Capital expenditure-$-10K-$-300K$0.00-$-20K$0.00
Free cash flow-$-14.83M-$-17.65M-$-12.74M-$-16.84M-$-15.05M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Allarity Therapeutics, Inc.

        Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.

        CEO
        Thomas H. Jensen
        Employees
        7
        Beta
        0.53

        Explore

        Frequently asked questions

        What is the intrinsic value of Allarity Therapeutics, Inc. (ALLR)?

        InvestorsCraft does not currently publish an intrinsic value for ALLR. How the IC value is calculated.

        Is ALLR undervalued?

        InvestorsCraft does not publish an undervaluation signal for ALLR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.